Wilex, Prometheus in Potential $145M Deal for Rencarex
By Cormac Sheridan
Friday, May 6, 2011
Shares in Wilex AG rose almost 20 percent earlier this week on news that the company secured $19 million up front and could bank another $20 million within 12 months as part of a U.S. deal with Prometheus Laboratories Inc. for its Phase III anticancer antibody Rencarex (girentuximab), which is potentially worth more than $145 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.